Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe and ZENEO®
Status:
Not yet recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Primary objective of this study is
- To demonstrate whether an intramuscular (i.m.) injection of the test product (10 mg /
0.625 mL) on bare skin in the thigh, and the i.m. injection of either the reference
product, HYPNOVEL® (10 mg/ 2 mL) or the i.m. injection of 2mL of the reference product,
DORMICUM® (15 mg/ 3 mL) or the i.m injection of 2mL of the reference product, DORMICUM®
(5 mg/ 1 mL) administered with a conventional syringe in the thigh on bare skin, are
bioequivalent